STOCK TITAN
  1. Home
  2. Sec-filings
  3. TMCI
  4. [Form 4] TREACE MEDICAL CONCEPTS, INC. Insider Trading Activity

TMCI (TMCI) Chief Innovation Officer exercises options, granted RSUs

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Treace Medical Concepts Chief Innovation Officer Sean F. Scanlan reported equity transactions in company stock. On January 21, 2026, he exercised a stock option for 53,500 shares of Common Stock at an exercise price of $0.72 per share, converting a previously held option into directly owned shares. On January 22, 2026, he received a grant of 262,500 restricted stock units (RSUs), each RSU representing one future share of Common Stock upon vesting. The RSUs vest in equal annual installments over four years from January 22, 2027 through January 22, 2030, contingent on his continued service with the company.

Positive

  • None.

Negative

  • None.
Insider Scanlan Sean F.
Role Chief Innovation Officer
Type Security Shares Price Value
Grant/Award Common Stock 262,500 $0.00 --
Exercise Stock Option (Right to Buy) 53,500 $0.00 --
Exercise Common Stock 53,500 $0.72 $39K
Holdings After Transaction: Common Stock — 689,599 shares (Direct); Stock Option (Right to Buy) — 0 shares (Direct)
Footnotes (1)
  1. Includes 283,948 restricted stock units. Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, with the first installment vesting on January 22, 2027 and the last installment vesting on January 22, 2030; subject to Reporting Person's providing continued service to Issuer through each vesting date. Includes 511,291 restricted stock units The stock option vested in equal annual installments over 4 years, commencing on January 26, 2016 with the last installment vesting on January 26, 2020.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Scanlan Sean F.
(Last) (First) (Middle)
C/O TREACE MEDICAL CONCEPTS, INC.
100 PALMETTO PARK PLACE
(Street)
PONTE VEDRA FL 32081
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
TREACE MEDICAL CONCEPTS, INC. [ TMCI ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Innovation Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/21/2026 M 53,500 A $0.72 427,099(1) D
Common Stock 01/22/2026 A 262,500(2) A $0 689,599(3) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $0.72 01/21/2026 M 53,500 01/26/2020(4) 01/26/2026 Common Stock 53,500 $0 0 D
Explanation of Responses:
1. Includes 283,948 restricted stock units.
2. Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, with the first installment vesting on January 22, 2027 and the last installment vesting on January 22, 2030; subject to Reporting Person's providing continued service to Issuer through each vesting date.
3. Includes 511,291 restricted stock units
4. The stock option vested in equal annual installments over 4 years, commencing on January 26, 2016 with the last installment vesting on January 26, 2020.
/s/ Lisa Taylor as Attorney-in-fact for Sean Scanlan 01/23/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did TMCI Chief Innovation Officer Sean F. Scanlan report?

Sean F. Scanlan reported two transactions: on January 21, 2026, he exercised a stock option into 53,500 shares of Common Stock at $0.72 per share, and on January 22, 2026, he received a grant of 262,500 restricted stock units (RSUs).

What is the size and vesting schedule of the new RSU grant for TMCI’s Chief Innovation Officer?

The grant consists of 262,500 RSUs, each convertible into one share of Common Stock upon vesting. The RSUs vest in four equal annual installments, with the first vesting on January 22, 2027 and the final installment on January 22, 2030, subject to continued service.

At what price did Sean F. Scanlan exercise his Treace Medical Concepts stock options?

On January 21, 2026, he exercised a stock option covering 53,500 shares of Treace Medical Concepts Common Stock at an exercise price of $0.72 per share.

How many Treace Medical Concepts shares did Sean F. Scanlan hold after the option exercise reported on January 21, 2026?

Following the January 21, 2026 option exercise, Sean F. Scanlan directly beneficially owned 427,099 shares of Treace Medical Concepts Common Stock, which included previously reported restricted stock units as noted in the filing.

How many Treace Medical Concepts shares did Sean F. Scanlan beneficially own after the January 22, 2026 RSU grant?

After the January 22, 2026 RSU grant, Sean F. Scanlan beneficially owned 689,599 shares of Treace Medical Concepts Common Stock, including 511,291 restricted stock units referenced in the footnotes.

What role does Sean F. Scanlan hold at Treace Medical Concepts (TMCI)?

Sean F. Scanlan is reported as an officer of Treace Medical Concepts with the title of Chief Innovation Officer.